Cystic in Biological Technology

Phase 3 Cystic Fibrosis Trial Results Presented at European Conference

... Phase III trial of Bronchitol in patients with cystic fibrosis have been presented at the 2009 European cystic Fibrosis Conference in Brest, France. The ... are planned to be presented at the North American cystic Fibrosis conference in Minneapolis in October. ...

PTC Therapeutics Receives $2.6 Million in Government Grants

... orphan drug status for the treatment of DMD and cystic fibrosis due to nonsense mutations. The FDA has ... has also been supported by grants from the cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the cystic Fibrosis Foundation), FDA's Office of Orphan ...

Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer

... therapy for the prevention of exacerbations in cystic fibrosis (CF) and chronic obstructive pulmonary ... the quality of lives for patients suffering from cystic fibrosis or COPD. Exacerbations remain a ... the prevention of exacerbations in patients with cystic fibrosis and COPD. MP-376 is currently in Phase 2 ...

Chronic Lung Disease - Axentis Pharma Attracts Investment Interest

... potential to cater to unmet medical needs such as cystic fibrosis and other respiratory diseases. In the ... which leads to rapid cell death. About cystic fibrosis cystic fibrosis is the most common life-threatening ...

Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411

... new treatment option for patients suffering from cystic fibrosis, COPD and other serious lung ... chronic obstructive pulmonary disorder (COPD), cystic fibrosis, bronchiactesis and Sjogren's syndrome. ... from the National Institutes of Health (NIH) and cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) For ...

Transave, Inc. Secures $12.5 Million in New Financing

... aeruginosa, a lung infection common in cystic fibrosis (CF) patients. The improvement in lung ... The data were presented at the European cystic Fibrosis Society Conference in Prague, Czech Republic. cystic Fibrosis Foundation Therapeutics, the nonprofit ...

Pigs bred with cystic fibrosis provide model to mimic human disease

... COLUMBIA, Mo. cystic Fibrosis (CF) continues to be a lethal disease ... Missouri researcher is producing pigs born with cystic fibrosis that mimic the exact symptoms of a ... for the potential it has to move research on cystic fibrosis forward." ...

40 High-Achieving Students with Cystic Fibrosis Receive $100,000 Total in Higher Education Scholarships From SolvayCARES(SM)

... be honored with a scholarship totaling $10,000. cystic fibrosis presents extraordinary health burdens ... more are pursuing dreams of higher education. cystic fibrosis is an inherited chronic disease that ... at http://www.solvay.com . References: (1) cystic Fibrosis Foundation. ...

PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet

... demonstrates activity in nonsense-mutation cystic fibrosis (CF). The data show that treatment with ... ) Patients with CF lack adequate levels of the cystic fibrosis transmembrane conductance regulator ... for approximately 10 percent of the cases of cystic fibrosis worldwide. However, in Israel, nonsense ...

Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases

... dystrophy (DMD), and a phase 2b trial in cystic fibrosis (CF) is expected to begin by the end of ... States. Genzyme has extensive experience with cystic fibrosis, having conducted more than six clinical ... 2a clinical trials in nonsense-mutation-mediated cystic fibrosis and in nonsense-mutation-mediated ...

Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technology

... an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech ... by a new approach to the treatment of cystic fibrosis and secured the relevant rights. The technology directly targets the functional cause of cystic fibrosis - the process whereby the body destroys ...

PTC124 Featured at Third Annual Congress of Myology

... program. Genetic disorders, such as DMD and cystic fibrosis (CF), are caused by genetic alterations, ... muscular dystrophy (DMD) and cystic fibrosis (CF). PTC124 is potentially applicable ... from the Muscular Dystrophy Association (MDA), cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), ...

Nektar Receives Patent Covering Pulmonary Targeted Antibiotics

... treatment of Pseudomonas aeruginosa pneumonia. cystic fibrosis patients are susceptible to ... remains at the forefront of our fields." About cystic Fibrosis cystic fibrosis (CF) is a genetic disease. About 30,000 ...

Cystic Fibrosis Trial In Children Returns Positive Data

... that a Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function ... statistical conclusion. People affected by cystic fibrosis typically experience a decline in lung ... major pharmaceutical markets are affected with cystic fibrosis and no products have been approved to ...

Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients

... aeruginosa lung infections in patients with cystic fibrosis, according to results of a study ... barrier for bacteria. This prevents patients with cystic fibrosis (CF) from clearing infections even under ... ). The cystic Fibrosis Foundation provided a $1.7 million award ...

Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis

... aeruginosa and other bacteria in patients with cystic fibrosis. Levofloxacin is the active ... solution for inhalation. Patients with cystic fibrosis (CF) suffer from chronic infections ... "Obtaining orphan drug designation for MP-376 in cystic fibrosis is an important milestone for the ...

Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections

... of a drug delivery system for lung infections in cystic Fibrosis patients was signed today. As part ... of therapy against lung infections in cystic Fibrosis patients. Under the terms of the ... This is a very promising prospect for both cystic Fibrosis patients and investors in Axentis." ....

PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis

... Pediatric Data Presented at 21st North American cystic Fibrosis Conference Confirm Previous ... in a measure of the function of the cystic fibrosis transmembrane conductance regulator ... Division Chief, at the 21st North American cystic Fibrosis Conference in Anaheim, California. ...

GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis

... suite for the integration and analysis of cystic fibrosis data. GeneGo's proprietary software ... and networks. "We are very pleased to work with cystic Fibrosis Foundation and the academic community ... this project." The project will be guided by a cystic Fibrosis Foundation committee with a goal to ...

BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco

... Molecular Chaperones Target Underlying Defect in cystic Fibrosis; CFTR Folding ... significantly extended and improved the lives of cystic fibrosis patients," said Dr. Alan Verkman, Professor of Medicine and Physiology and Director of the cystic Fibrosis Research Development Program at the ...

Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury

... lung disease, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The studies will be supported by Grant Number ... mucosal defenses, including chronic obstructive pulmonary disorder (COPD), cystic fibrosis, bronchiactesis and Sjogren's syndrome. Parion's lead product ...

NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008

... and preclinical development programs in onychomycosis, herpes labialis, cystic fibrosis and an intra-nasal influenza vaccine during the joint meeting of ... for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and mucosal vaccines for influenza and hepatitis B. Company ...

Regulatory Path for Bronchitol in Bronchiectasis

... as a treatment to improve mucus clearance in the lungs of patients with cystic fibrosis, bronchiectasis and chronic obstructive pulmonary diseases. ... basis of a marketing approval for Bronchitol in Europe in patients with cystic fibrosis is currently actively recruiting. CONTACT: Alan Robertson - ...

JCI online early table of contents: March 6, 2008

... EDITOR'S PICK: Genetic manipulation might model cystic fibrosis cystic fibrosis (CF) is caused by mutations in the gene responsible for making ...

Data show a decline in cystic fibrosis since introduction of prenatal carrier screening

... state of Massachusetts has offered universal newborn screening to detect cystic fibrosis (CF) since 1999. Independently, recommendations for nationwide ... and the American College of Medical Genetics. Newborn screening for cystic fibrosis (much like newborn screening for other conditions), a public ...

Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer

... for the treatment of chronic respiratory infections in patients with cystic fibrosis and other serious lung diseases." "In addition, we are eager to ... the treatment of chronic lung infections due to Pseudomonas aeruginosa in cystic fibrosis patients. The company is also pursuing applications related to ...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

... Commercial Launch Plans - The company is on track to launch three diagnostic products through its CLIA laboratory by the first quarter of 2010 - cystic fibrosis carrier screen (CFTR), RHD and fetal sex determination. The first of these tests - CFTR - is expected to launch this quarter or early next ...

Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria

... said Tim Whitten, chief executive officer of Transave. "The preliminary success with ARIKACE demonstrating a sustained clinical benefit in treating cystic fibrosis (CF) patients with Pseudomonas lung infections is encouraging as we tackle this additional disease state in collaboration with NIAID." ...

Pharmaxis Announces Placement of $47 Million and Share Purchase Plan

... plan will be capped at A$10 million. "The proceeds from this offering are principally to be used for the commercial launch of Bronchitol for cystic fibrosis in both Europe and the U.S. This placement means Pharmaxis can take an important additional step in building a profitable, international, ...

A Global View: NanoLogix Creates Science Advisory Board

... and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical, Defense, and homeland security applications, NanoLogix technology is applicable in ...

NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents

... and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical, Defense, and homeland security applications, NanoLogix technology is applicable in ...

NanoLogix Begins Construction of Production Facility for Medical Test Kits

... and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, ...

New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague

... and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, ...

NanoLogix Adds Noted Journalist Bill Scanlon to Provide Media Relations

... and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, ...

NanoBio Corporation Raises $12 Million in Series B Financing

... be used by the company to complete a phase 1 study investigating a novel topical treatment for acne, preclinical studies on a nebulized therapy for cystic fibrosis, and a phase 1 study for an intranasal seasonal influenza vaccine. This funding follows several recent product announcements by ...

Pharmaxis Builds Senior Management Team

... for chronic respiratory and immune disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded ...

BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015

... with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and cystic fibrosis. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline. Lexiva is a registered trademark of the ...

VivoMetrics to Present at the 2009 Biotech Showcase

... across a wide range of disease states, including sleep disordered breathing, congestive heart failure, chronic obstructive pulmonary disease and cystic fibrosis. For more information, visit www.lifeshirt.com . Forward-looking Statements This press release contains forward-looking ...

MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose's Electronic Dry Powder Inhaler

... and are used in pharmaceutical clinical trials and respiratory disease management applications for chronic obstructive pulmonary disease, asthma and cystic fibrosis. SmartinhalerLive(TM) uses wireless communications technology to provide real time data collection and reporting from drug delivery ...

Nephros Provides Corporate Update

... practices. In cases where the levels of these pathogens may not pose much threat to healthy water users, immuno-compromised patients such as cancer, cystic fibrosis, HIV, organ transplant, and burn patients may have a substantial risk of infection. Nephros's DSU filtration products are an effective ...